[en] Smallpox is the first viral infection to have been eradicated world-wide. This remarkable success is due to several factors including the availability of an efficacious vaccine and the absence of a wildlife reservoir. The only animal virus disease sharing these characteristics is rinderpest, for which there are several efficacious vaccines. Other animal viral infections do not share the same characteristics, either due to the lack of an efficacious vaccine (African swine fever), or to the existence of wildlife reservoirs such as the wild boar for classical swine fever, the African buffalo for foot-and-mouth disease, bats for lyssavirus infections, etc. These diseases are more prone to regional elimination than a complete worldwide eradication. Two methods are used to eliminate an animal viral infection, either vaccination or the strict application of hygienic measures including stamping out and incineration, or the combination of both methods. Public opinion is more and more concerned about stamping out, even when necessary such as when dealing with emerging zoonoses. On the other hand, generalised vaccination (i.e. against foot-and-mouth disease, classical swine fever, etc.) may be discontinued despite its efficacy, for macro-economical reasons. The solution may come from the use of marker vaccines associated with companion diagnostic tests to make a distinction between infected and immunised animals by serological examination. Current control and eradication programmes against these and other diseases, the role of marker vaccines, and the limitations of such programmes are being discussed.
Fenner F, Henderson DA, Anta L, Jesek Z, Ladnyi ID: Smallpox and its eradication. World Health Organisation, Geneva, 1988.
Fenner F: A successful eradication campaign: global eradication of smallpox. Rev Infect Dis 1982; 4: 916-930.
Domingo E: Vers une compréhension des virus comme systèmes complexes et dynamiques. Ann Méd Vét 1999; 143: 225-235.
Plowright W: La peste bovine aujourd'hui dans le monde. Contrôle et possibilité d'éradication par la vaccination. Ann Méd Vét 1985; 129: 9-32.
Yamanouchi K: New approaches for rinderpest vaccine, in Pastoret PP, Blancou J, Vannier P, Verschueren C (eds): Veterinary Vaccinology. Elsevier Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo 1997, pp 657-661.
Taylor WP: Vaccination against rinderpest, in Pastoret PP, Blancou J, Vannier P, Verschueren C (eds): Veterinary Vaccinology. Elsevier Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo 1997, pp 653-656.
Pastoret PP, Brochier B: The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies, a link between Jenner and Pasteur. Epidemiol Infect 1996; 116: 235-240.
Brochier B, Dechamps P, Costy F, Hallet L, Leuris J, Villers J, Péharpré D, Mosselmans F, Beier R, Lecomte L, Mullier P, Roland H, Bauduin B, Kervyn T, Renders C, Escutenaire S, Pastoret PP: Elimination de la rage en Belgique par la vaccination du renard roux (Vulpes vulpes). Ann Méd Vét 2001; 145: 293-305.
Mohdnor MN, Gan CH, Ong BL: Nipah virus infection of pigs in peninsular Malaysia. Rev Sci Tech OIE 2000; 19(1): 160-165.
Mignon B, Waxweiler S, Thiry E, Boulanger D, Dubuisson J, Pastoret PP: Epidemiological evaluation of a monoclonal ELISA detecting bovine diarrhoea pestivirus antigen in field blood samples of persistently infected cattle. J Virol Methods 1992; 40: 85-94.
Pastoret PP, Thiry E, Brochier B, Derboven G, Vindevogel H: The role of latency in the epizootiology of infectious bovine rhinotracheitis, in Wittmann G, Gaskell RM, Rziha HJ (eds): Latent herpesvirus infections in veterinary medicine. Martinus Nijhoff Publishers, for the Commission of the European Communities, 1984.
Pastoret PP, Thiry E, Thomas R: Logical description of bovine herpesvirus 1. latent infection. J Gen Virol 1986; 67: 885-897.
Van Oirschot JT, Gielkens ALJ, Moormann RJM, Berns AJM: Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease. Vet Microbiol 1990; 23: 85-101.
Bartha A: Experiments to reduce the virulence of Aujeszky's virus. Magy Allartov Lapja 1961; 16:42-45.
Pastoret P-P, Babiuk LA, Misra V, Griebel P: Reactivation of temperature-sensitive and non-temperature-sensitive infectious bovine rhinotracheitis vaccine virus with dexamethasone. Infect Immun 1980; 29: 483-488.
Pastoret P-P, Detal G, Dive M, Waxweiler S, Weelemans G, Marcourt J, Magnonet P, Dernelle E: Mesures à prendre au centre de sélection bovine de Ciney en vue de répondre aux nouvelles normes sanitaires imposées par la Commission des Communautés Européennes. Ann Med Vet 1989; 133: 247-256.
Limbourg B, Kerkhofs P, Massard C, Michelet S, Saegerman C, Thiry E: Avantages et inconvénients d'un plan de lutte contre la rhinotrachéite infectieuse bovine en Belgique. Ann Méd Vét, in press.
Biront P, Leunen J, Vandeputte J: Inhibition of virus replication in the tonsils of pigs previously vaccinated with a Chinese strain vaccine and challenged oronasally with a virulent strain of classical swine fever virus. Vet Microbiol 1987; 14: 105-113.
Leunen J, Strobbe R: Capacity of attenuated swine fever vaccines to prevent virus carriers hi the vaccinated pigs after contact with field virus. Arch Exp Vet Med 1977:31; 533-536.
Van Zijl M, Wensvoort G, De Kluyver E, Hulst M, Vander GH, Gielkens A, Berns A, Moormann R: Live attenuated pseudorabies virus expressing envelope glycoprotein El of hog cholera virus, protects swine against both pseudorabies and hog cholera. J Virol 1991; 65: 2761-2765.
Van Rijn PA, Van Gennip HG, Moormann RJ: An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV). Vaccine 1999; 17: 433-440.
Dewulf J, Laevens H, Koenen F, Mintiens K, De Kruif A: An E2 sub-unit marker vaccine does not prevent horizontal or vertical transmission of classical swine fever virus. Vaccine 2001:20; 86-91.
Vandeputte J, Chappuis G: Classical swine fever: the European experience and a guide for infected areas. Rev Sci Tech OIE 1999; 18: 638-647.
Lombard M: Constitution d'une banque d'antigènes congelés et préparation d'urgence des vaccins anti-aphteux. Ann Méd Vét 1992; 136: 523-524.
Salt JS: Vaccination against foot and mouth disease, Pastoret PP, Blancou J, Vannier P, Verschueren C (eds): Veterinary Vaccinology. Elsevier Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo 1997, pp 641-652.
Declercq C: La vaccination comme outil de lutte contre la fièvre aphteuse. Ann Méd Vét 2002, in press.
De Diego M, Brocchi E, Mackay D, de Simone F: The non-structural polyprotein 3 ABC of foot-and-mouth disease virus as a diagnostic antigen ELISA to differentiate infected from vaccinated cattle. Arch Virol 1997; 142: 2021-2033.
Pastoret PP, Brochier B, Blancou J, Artois M, Aubert M, Kieny MP, Lecocq JP, Languet B, Chappuis G, Desmettre P: Development and deliberate release of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies, Binns MM, Smith GL (eds): Recombinant Poxviruses, CRC Press, Baton Roca, USA 1992, pp 163-206.
Pastoret PP, Brochier B, Languet B, Thomas I, Paquot A, Bauduin B, Costy F, Antoine H, Kieny MP, Lecocq JP, Debruyn J, Desmettre Ph: First field trial of fox vaccination against rabies with a vaccinia-rabies recombinant virus. Vet Rec 1988; 123: 481-483.
Brochier B, Costy F, De Coninck V, Hallet L, Bourhy H, Peharpré D, Mosselmans F, Beyer R, Lecomte L, Mullier P, Bauduin B, Pastoret PP: Epidémio-surveillance de la rage en Belgique: recrudescence en 1994. Ann Méd Vét 1995; 139: 263-273.
Loza Rubio E, Aguilar-Setién A, Bahloul Ch, Brochier B, Pastoret PP, Tordo N: Discrimination between epidemiological cycles of rabies virus in Mexico. Arch Med Res 1999; 30: 144-149.
McColl KA, Tordo N, Aguilar-Setién A: Bat lyssavirus infections. Rev Sci Tech OIE 2000; 19: 177-196.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.